连全球医疗资源，享前沿医疗服务
4006 776 356
免费咨询 9:00-18:00
免费获得国外相关药品，最快 1 个工作日回馈药物信息
出境医 / 临床实验 / An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
Study Description
Brief Summary:
The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant) clinical study to continue to have access to rimegepant while collecting ongoing safety data.
(NOTE: ONLY FOR PATIENTS who participated in a previous BHV-3000/Rimegepant Clinical Trial in the past)
| Condition or disease | Intervention/treatment |
|---|---|
| Migraine | Drug: rimegepant |
Study Design
| Study Type : | Expanded Access |
| Expanded Access Type : | Treatment IND/Protocol |
| Official Title: | BHV3000-401: An Open-label, Intermediate-size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine |
Arms and Interventions
Outcome Measures
Eligibility Criteria
Contacts and Locations
| Tracking Information | |
|---|---|
| First Submitted Date | April 29, 2019 |
| First Posted Date | May 1, 2019 |
| Last Update Posted Date | March 3, 2020 |
| Descriptive Information | |
| Brief Title | An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine |
| Brief Summary |
The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant) clinical study to continue to have access to rimegepant while collecting ongoing safety data. (NOTE: ONLY FOR PATIENTS who participated in a previous BHV-3000/Rimegepant Clinical Trial in the past) |
| Detailed Description | Not Provided |
| Study Type | Expanded Access |
| Expanded Access Type | Treatment IND/Protocol |
| Intervention | Drug: rimegepant
rimegepant 75 mg
|
| Publications * | Not Provided |
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|
| Recruitment Information | |
| Expanded Access Status | No longer available |
| Contacts | Contact information is only displayed when the study is recruiting subjects |
| Listed Location Countries | Not Provided |
| Removed Location Countries | |
| Administrative Information | |
| NCT Number | NCT03934086 |
| Responsible Party | Biohaven Pharmaceuticals, Inc. |
| Study Sponsor | Biohaven Pharmaceuticals, Inc. |
| Collaborators | Not Provided |
| Investigators | Not Provided |
| PRS Account | Biohaven Pharmaceuticals, Inc. |
| Verification Date | February 2020 |
